Perfluorododecanoic acid
Based on 1 Customer Validation
Perfluorododecanoic acid (PFDoA) is an orally active, blood-brain barrier-permeable perfluorinated compound. Perfluorododecanoic acid increases Caspase 3 activity, disrupts mitochondrial membrane potential, and elevates ROS levels. Perfluorododecanoic acid induces cognitive deficits. Perfluorododecanoic acid exhibits hepatotoxicity.
For research use only. We do not sell to patients.
- Purity : 98.1%
- CAS No.: 307-55-1
- Formula: C12HF23O2
- Molecular Weight:614.10
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Caspase 3 |
In Vitro
Perfluorododecanoic acid (25-100 μM; 24 h) reduces the viability of PC12 cells in a dose-dependent manner[2].
Perfluorododecanoic acid (50-100 μM) induces oxidative stress in PC12 cells and significantly increases the levels of ROS and MDA[2].
Perfluorododecanoic acid (50-100 μM) disrupts the mitochondrial membrane potential of PC12 cells, resulting in a significant reduction in membrane potential[2].
Perfluorododecanoic acid (100 μM) activates Caspase 3 in PC12 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:PC12
-
Concentration:25 μM, 50 μM, 100 μM
-
Incubation Time:24 h
-
Result:Decreased PC12 cell viability in a dose-dependent manner.
Decreased cell viability by 1.23-fold (p < 0.05) at 50 μM.
Decreased cell viability by 1.39-fold (p < 0.05) at 100 μM.
In Vivo
Perfluorododecanoic acid (5-50 mg/kg; p.o.; single dose) accumulates in the brain of adult male Wistar rats after a single oral dose, inducing dose-dependent cognitive deficit that persists for at least 30 days and increasing time spent in open arms in the elevated-plus maze test at 50 mg/kg[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Danio rerio (adult female)[1]
-
Dosage:20 μg/g body weight; 40 μg/g body weight; 80 μg/g body weight
-
Administration:i.p.; single injection
-
Result:Caused hepatocyte swelling at 7 days post-injection (20 μg/g dose).
Caused obscured cell borders and vacuolar degeneration at 7 days post-injection (40 μg/g dose).
Caused severe hepatic lesions including nuclei enlargement, pycnosis, hepatocyte necrosis, cytolysis, and near-collapse of cellular structure at 7 days post-injection (80 μg/g dose).
Induced dose-dependent decreases in GSH content of 14%, 26%, 29% respectively at 48 h post-injection.
Caused 14% and 12% decreases in GSH content at 96 h post-injection (20 μg/g and 80 μg/g doses respectively).
Caused significant depletion of GSH content at 7 days post-injection (80 μg/g dose).
Caused significant decreases in SOD activity at 48 h post-injection (all doses).
Caused significant elevations in SOD activity compared to controls at 7 days post-injection (40 μg/g and 80 μg/g doses).
Showed time-related increases in SOD activity across all doses at 96 h and 7 days relative to 48 h.
Caused significant decreases in CAT activity at 48 h post-injection (all doses).
Caused a significant 1.4-fold reduction in CAT activity at 96 h post-injection (20 μg/g dose).
Induced significant dose-dependent increase in GPx activity at 48 h post-injection.
Caused a significant 1.6-fold increase in GPx activity at 7 days post-injection (80 μg/g dose).
Showed significantly decreased GPx activity at 7 days relative to 48 h (all doses).
Caused a significant 7-fold increase in hepatic lipid peroxidation (MDA) at 7 days post-injection (80 μg/g dose).
Caused a significant 2.8-fold decrease in L-FABP gene expression at 7 days post-injection (20 μg/g dose).
Induced dose-dependent significant decreases in PPARα gene expression of 1.6-fold, 2.2-fold, 2.5-fold respectively at 7 days post-injection.
Caused significant decreases in CPT-I gene expression of 2.0-fold, 1.6-fold, 2.2-fold respectively at 7 days post-injection.
Caused a significant 2.0-fold induction in MCAD gene expression at 7 days post-injection (40 μg/g dose); caused an elevation in MCAD gene expression at 7 days post-injection (80 μg/g dose).
Induced dose-dependent significant decreases in UCP-2 gene expression of 1.5-fold, 2.0-fold, 2.3-fold respectively at 7 days post-injection.
Caused significant decreases in Bcl-2 gene expression of 1.8-fold, 1.6-fold, 2.1-fold respectively at 7 days post-injection.
-
Animal Model:Wistar (male, 8 weeks old)[3]
-
Dosage:5 mg/kg; 20 mg/kg; 50 mg/kg
-
Administration:p.o.; single dose
-
Result:Reached a brain concentration of 44.4 μg/g tissue and serum concentration of 24.4 μg/mL 9 days post-dosing at 50 mg/kg.
Reached a brain concentration of 28.6 μg/g tissue 30 days post-dosing at 50 mg/kg.
Induced a significant decrease in discrimination index at doses ≥20 mg/kg on Days 6-7 post-dosing.
Caused a persistent discrimination index deficit through Day 30 post-dosing at 50 mg/kg, with no change in total exploration time at any dose or time point.
Triggered a decrease in discrimination index when brain concentrations exceeded 20 μg/g tissue.
Significantly increased time spent in open arms at 50 mg/kg, with no changes in distance traveled, total arm entries, or percentage of open arm entries.
Showed no significant differences in alternation percentage, total arm entries, distance traveled, number of crossings, time spent in the central area, or immobility time between 50 mg/kg and vehicle-treated rats.
Chemical Information
-
CAS No. 307-55-1
-
Appearance Solid
-
Molecular Weight 614.10
-
Formula C12HF23O2
-
Color White to off-white
-
SMILES
C(=O)(C(C(C(C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)O
-
Synonyms
PFDoA
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 5.83 mg/mL (9.49 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Fluorescent plasma-membrane potential dye assay
Fluorescent plasma-membrane potential dye assays measure changes in cell membrane potential using voltage-sensitive dyes whose fluorescence changes when cells depolarize or hyperpolarize. Anionic bis-oxonol dyes such as DiBAC4(3) enter depolarized cells more readily and show increased fluorescence after intracellular binding, while hyperpolarization reduces dye accumulation and fluorescence. FMP/FLIPR membrane-potential dyes are used for faster, homogeneous microplate assays of ion-channel or receptor-mediated membrane-potential changes.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Hepatotoxicity Study
This protocol evaluates hepatotoxicity using complementary in vivo mouse APAP acute liver injury and in vitro hepatocyte-based cytotoxicity readouts. In vivo APAP injury is assessed by serum ALT/AST, liver histology, hepatic glutathione, protein adducts, necrosis, inflammation, and regeneration-related endpoints. In vitro hepatotoxicity is assessed by loss of viability, leakage of ALT/AST/LDH, oxidative-stress markers, mitochondrial function, nuclear morphology, intracellular calcium, and high-content imaging endpoints.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (641 KB)
- English - EN (641 KB)
- Français - FR (641 KB)
- Deutsch - DE (641 KB)
- Norwegian - NO (641 KB)
- Español - ES (641 KB)
- Swedish - SV (641 KB)
- Italian - IT (641 KB)
- Korean - KR (641 KB)
- Portuguese - PT (641 KB)
-
Handling Instructions (2659 KB)
References
[1]. Liu Y, et al. Induction of time-dependent oxidative stress and related transcriptional effects of perfluorododecanoic acid in zebrafish liver. Aquat Toxicol. 2008;89(4):242-250. [Content Brief]
[2]. Fang X, et al. Oxidative stress and mitochondrial membrane potential are involved in the cytotoxicity of perfluorododecanoic acid to neurons. Toxicol Ind Health. 2020;36(11):892-897. [Content Brief]
[3]. Kawabata K, et al. Perfluorododecanoic Acid Induces Cognitive Deficit in Adult Rats. Toxicol Sci. 2017;157(2):421-428. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6284 mL | 8.1420 mL | 16.2840 mL | 40.7100 mL |
| 5 mM | 0.3257 mL | 1.6284 mL | 3.2568 mL | 8.1420 mL |
Keywords
- Perfluorododecanoic acid
- 307-55-1
- PFDoA
- Reactive Oxygen Species (ROS)
- Caspase
- Mitochondrial Metabolism
- female zebrafish
- uncoupling protein 2
- adult male Wistar rats
- peroxisome proliferating activating receptor β
- liver fatty acid binding protein
- Bcl-2
- medium-chain fatty acid dehydrogenase
- carnitine palmitoyl-transferase I
- caspase 3
- PC12 cells
- Inhibitor
- inhibitor
- inhibit